We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Generation Sequencing Fuels Bioinformatics Upswing

By LabMedica International staff writers
Posted on 25 Nov 2013
Print article
The falling cost of genome sequencing is driving momentum to the global next-generation sequencing (NGS) bioinformatics market. As cost-effective technology fuels adoption of genome sequencing in multiple end-user segments, a huge output of NGS data to store and analyze is an overwhelming result. Where primary and secondary data analysis tools are geared to become more valuable as pipelines standardize, the high-value tertiary data analysis segment used for biologic interpretation and clinical reporting will drive revenue growth, according to recent market research.

New analysis from Frost & Sullivan’s (Mountain View, CA, USA), an international growth consultancy firm, revealed that the market earned revenue of USD 170 million in 2012 and estimates this to reach USD 580 million in 2018 at a striking compound annual growth rate (CAGR) of 22.7%.

“With sequencing data production forecast to grow at a CAGR of more than 75% between 2012 and 2018, researchers will need efficient NGS informatics solutions to manage, analyze, and interpret this escalating amount of data,” said Frost & Sullivan life sciences senior industry analyst Christi Bird. “As the number of applications for NGS continues to grow, the implementation of NGS informatics will go up.”

However, customers employ NGS for a broad range of applications, and there is no perfect product for NGS informatics. Therefore, customers may have difficulty in identifying the appropriate tools for their needs. The wide variety of free public domain and commercial applications provided by more than 100 competitors in this field has also led to low barriers to entry, rising competition, and commoditization in specific product fields.

Furthermore, NGS users are frequently tentative in making further investments in commercial informatics tools, because of the range of public and open-source software available along with readily accessible internal bioinformatics resources. Therefore, in addition to the hurdles of commoditization and standardization, suppliers must persuade NGS users their commercial tools are better than free ones.

“As the market matures and informatics prices fall, competitors will rely not just on the expanding volume of users and NGS data developed but also on the high-value interpretation sector of the market to sustain profits globally,” remarked Ms. Bird. “Suppliers that can develop high-value, simple, and streamlined turnkey solutions will find success.”

Related Links:

Frost & Sullivan


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.